Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)
China
· Delayed Price · Currency is CNY 23.27
+0.69 (3.06%)
Mar 10, 2026, 3:00 PM CST
SHA:603538 Revenue
Ningbo Menovo Pharmaceutical had revenue of 439.46M CNY in the quarter ending September 30, 2025, with 28.80% growth. This brings the company's revenue in the last twelve months to 1.54B, up 24.54% year-over-year. In the year 2024, Ningbo Menovo Pharmaceutical had annual revenue of 1.37B with 12.85% growth.
Revenue (ttm)
1.54B
Revenue Growth
+24.54%
P/S Ratio
3.33
Revenue / Employee
623.21K
Employees
2,404
Market Cap
5.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.37B | 156.36M | 12.85% |
| Dec 31, 2023 | 1.22B | -240.48M | -16.51% |
| Dec 31, 2022 | 1.46B | 198.83M | 15.80% |
| Dec 31, 2021 | 1.26B | 64.77M | 5.43% |
| Dec 31, 2020 | 1.19B | 13.17M | 1.12% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.18B |
| Bide Pharmatech | 1.32B |
| Newland Pharmaceutical | 670.43M |
| Zhejiang Yatai Pharmaceutical | 326.64M |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.74B |
| Hubei Biocause Heilen Pharmaceutical | 430.77M |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Nanjing Hicin Pharmaceutical | 615.39M |